tubulin inhibitor 1

Tubulin inhibitor 1 is an inhibitor of tubulin, inhibits tubulin polymerization, with potent anti-tumor activity, induces cellular apoptosis causes and cellular mitotic arrest in the G2 M phase.

Tubulin inhibitor 14 是一种有效的 NQO2（醌氧化还原酶 2）抑制剂，IC50 为 1.0 μM，也抑制微管蛋白聚合和内皮细胞毛细管样管的形成。Tubulin inhibitor 14 是一种微管去稳定剂，具有潜在的肿瘤选择性以及抗血管生成和血管破坏的功能[1]。

Tubulin inhibitor 17 (Compound 3b) 是微管蛋白聚合抑制剂（IC50 = 12.38 μM）。Tubulin inhibitor 17 显示出抗癌活性并且诱导细胞凋亡。

Tubulin inhibitor 15 是有效的微管蛋白抑制剂，具有抗增殖活性。Tubulin inhibitor 15 在 HepG2 细胞中表现出细胞毒性。

Tubulin inhibitor 16 是有效的微管蛋白抑制剂，具有抗增殖活性。Tubulin inhibitor 16 在 HepG2 细胞中表现出细胞毒性。

Tubulin inhibitor 12 (Hit 9) is a recently developed compound with potent inhibitory effects on tubulin (IC50 = 25.3 μM). This compound exhibits noteworthy anti-tumor and anti-proliferative activities, making it a promising candidate for the treatment of cancer [1].

Tubulin inhibitor 19 (compound 9b) is a potent indole chalcone compound that exhibits strong inhibitory activity against tubulin. Its potential in cancer research makes it valuable for studying cancer diseases [1].

Tubulin inhibitor 18 (compound 5j) is a highly potent chalcone compound that effectively inhibits tubulin. Its unique molecular structure renders Tubulin inhibitor 18 as a promising candidate for cancer research [1].

Tubulin inhibitor 13 (E27) 是一种有效的tubulin抑制剂，其对tubulin聚合的抑制IC50值为16.1 μM。该化合物不仅可以抑制癌细胞迁移和侵袭，还能诱导apoptosis，显示出抗癌活性。

Tubulin inhibitor 11 是一种口服活性的有效微管蛋白抑制剂。它通过靶向秋水仙碱结合位点，抑制tubulin聚合，进而促进有丝分裂阻断和apoptosis。

Ixabepilone (Azaepothilone B) 是一种可口服的微管抑制剂，能够与微管蛋白结合，促进微管蛋白的聚合和微管的稳定，使细胞停滞在 G2-M 期，诱导细胞凋亡。

MKC-1 (Ro-31-7453) 是一种口服生物可利用的小分子双吲哚基马来酰亚胺细胞周期抑制剂，具有潜在的抗肿瘤活性。

Docetaxel trihydrate (RP-56976 Trihydrate) 是一种抗肿瘤试剂，抑制微管解聚的IC50值为 0.2 μM。它是紫杉醇的半合成类似物，能减弱 bcl-2 和 bcl-xL 基因表达的影响。它阻滞G2 M 细胞周期，导致细胞凋亡。

Tubulin inhibitor 6 (iHAP1) 是一种微管蛋白抑制剂，抑制微管蛋白聚合，IC50为 0.87 μM。它抑制多种癌细胞系，抑制 K562 细胞生长，IC50为 840 nM。

CHM-1 是细胞凋亡的诱导剂，通过激活 Cdc2 激酶活性在人肝细胞癌中显示出有效的抗肿瘤能力。 CHM-1 在体外和体内抑制微管蛋白聚合。

Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) 是一种靶向人表皮生长因子受体2 (HER2) 的 ADC，作为 T-DM1 的活性代谢产物含有微管蛋白聚合抑制剂 DM1，可抑制微管蛋白聚合，常用于乳腺癌的研究。

1-Naphthohydroxamic acid 是一种选择性 HDAC8抑制剂，IC50为 14 μM。它对 HDAC8的选择性高于 I 类 HDAC1 和 II 类 HDAC6，IC50大于100 μM，可诱导微管蛋白乙酰化。

Indibulin (D 24851) 是一种口服有效的微管蛋白合成抑制剂，具有抗有丝分裂和抗肿瘤活性，且神经毒性小。它降低了肌间神经张力，产生异常的纺锤体，激活有丝分裂检查点蛋白 Mad2 和 BubR1，并诱导有丝分裂停滞和细胞凋亡。

DBCO-(PEG2-VC-PAB-MMAE)2 consists of Monomethyl auristatin E (MMAE), a toxin payload in antibody-drug conjugate [1], conjugated to the cleavable linker DBCO-(PEG2-VC-PAB)2. MMAE, a potent tubulin inhibitor, serves as the cytotoxic component in this formulation.

MAL-di-EG-Val-Cit-PAB-MMAF refers to a chemical compound that comprises the linker (MAL-di-EG-Val-Cit-PAB) and the potent blocker of tubulin polymerization (MMAF, Monomethyl auristatin F)[1].

MC-Alkyl-Hydrazine Modified MMAF is a potent antitumor drug-linker conjugate for ADC, incorporating Modified MMAF, a tubulin inhibitor, through a noncleavable MC-Alkyl-Hydrazine linkage[1].

AZ1508, a tubulin inhibitor[1], serves as a drug-linker conjugate for antibody-drug conjugates (ADC) targeting breast and stomach cancer treatment.

SC-VC-PAB-DM1 is a drug-linker conjugate utilized in Antibody-Drug Conjugates (ADC), featuring DM1 (Mertansine, a tubulin inhibitor) linked through the SC-VC-PAB[1] ADC linker to deliver potent antitumor activity.

SC-VC-PAB-MMAE is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADCs), comprising the anti-mitotic agent monomethyl auristatin E (MMAE, a tubulin inhibitor) connected through the cleavable linker SC-VC-PAB[1].